This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Other. Active years: 2019.
Company Filing History:
1 out of 834,411 Years Active: 2019
Title: Juha Himanen: Innovator in Cancer Treatment
Introduction
Juha Himanen is a notable inventor based in New York, NY (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. His work focuses on addressing conditions related to the overexpression of EphA2, a critical factor in cancer progression.
Latest Patents
Juha Himanen holds a patent for "Methods and compositions for cancer treating conditions relating to over expressions of EphA2." This patent describes an anti-EphA2 scFv single-chain antibody that binds with high specificity to EphA2, effectively blocking ephrin binding to EphA2. The antibody can be linked with other antigen-targeting domains, such as an anti-CD20 domain, or conjugated with toxins. It may also be utilized in combination therapy for treating conditions associated with EphA2 overexpression. Furthermore, the antibody can be expressed in vivo using an expression vector designed to facilitate such treatment. He has 1 patent to his name.
Career Highlights
Throughout his career, Juha Himanen has worked with prestigious institutions, including Memorial Sloan Kettering Cancer Center. His research has contributed to advancements in cancer therapies, showcasing his commitment to improving patient outcomes.
Collaborations
Juha has collaborated with esteemed colleagues, including Dimitar B Nikolov and Urpo Lamminmaki. These partnerships have further enhanced his research and development efforts in the field of cancer treatment.
Conclusion
Juha Himanen's innovative work in cancer treatment exemplifies the impact of targeted therapies in modern medicine. His contributions continue to pave the way for advancements in the fight against cancer.